secwatch.observer — SEC 8-K summary
======================================

Issuer:     NextCure, Inc. (NXTC)
CIK:        0001661059
Form:       8-K
Filed at:   2025-01-10T23:59:59+00:00
Accession:  0001558370-25-000099
Event type: other_material
Sentiment:  neutral
Materiality: 0.60
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

NextCure doses first patient in Phase 1 study of B7-H4 ADC LNCB74 for multiple cancers
--------------------------------------------------------------------------------

- First patient dosed in Phase 1 study of LNCB74, a B7-H4-targeting ADC.
- LNCB74 is being developed as a therapeutic for treating multiple cancers.
- FDA cleared the IND for LNCB74 in December 2024.
- LNCB74 is developed in partnership with LigaChem Biosciences.
- Phase 1 aims to evaluate safety, tolerability, and preliminary anti-tumor activity.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1661059/000155837025000099/0001558370-25-000099-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1661059/000155837025000099/nxtc-20250110x8k.htm
  HTML page:      https://secwatch.observer/filing/0001558370-25-000099

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer